In this article, we will discuss Amsacrine (Oncology-2). So, let’s get started.
Although not fully reported, early trials in which amsacrine was given orally
failed to reach the maximum tolerated dose, as shown by lack of toxicity even at doses as high as 500 mg/m2 per day, suggesting incomplete or erratic absorption. In subsequent studies, the intravenous route was used, with which the maximum tolerated dose in patients with solid tumours is 100–150 mg/m2 when administered over 1–3 h (described by Louie & Issell, 1985).